A pair of phase 3 clinical trial results show favorable safety and IOP-lowering effects in glaucoma and ocular hypertension.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results